PALI on Nasdaq

PALISADE BIO, INC.

American biological products company based in Carlsbad, listed on Nasdaq (PALI).

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with CytRx, Artiva Biotherapeutics, Inc. or Inhibikase Therapeutics, Inc., or pick any stock.

  • TickerPALI on Nasdaq
  • IndustryBiological Products, (No Diagnostic Substances)
  • HeadquartersDE
  • Incorporated inDE2
  • Business address7750 El Camino Real, Suite 5200, Carlsbad, Ca 920092
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-13.0%Return on equity3

Financial statements

Revenue4563$0 in 2025
0$100.0K$200.0K$300.0K2019: $15.4K$15.4K20192020: $13.5K$13.5K2020−12%2022: $0$020222023: $250.0K$250.0K20232024: $0$020242025: $0$02025
Operating income478563-$18.1M in 2025+109% since 2019
-$60.0M-$40.0M-$20.0M02019: -$8.6M-$8.6M20192020: -$9.3M-$9.3M2020+8%2021: -$41.9M-$41.9M2021+350%2022: -$15.7M-$15.7M2022−62%2023: -$13.1M-$13.1M2023−17%2024: -$14.9M-$14.9M2024+14%2025: -$18.1M-$18.1M2025+22%
Net income478563-$16.8M in 2025+101% since 2019
-$30.0M-$20.0M-$10.0M02019: -$8.4M-$8.4M20192020: -$10.3M-$10.3M2020+24%2021: -$26.6M-$26.6M2021+158%2022: -$14.3M-$14.3M2022−46%2023: -$12.3M-$12.3M2023−14%2024: -$14.4M-$14.4M2024+17%2025: -$16.8M-$16.8M2025+16%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development$10.2M$9.1M
General and administrative$7.9M$5.8M
Total operating expenses$18.1M$14.9M
Loss from operations-$18.1M-$14.9M
Interest expense-$10.0K-$12.0K
Other income, net$1.3M$433.0K
Total other income, net$1.3M$421.0K
Net loss-$16.8M-$14.4M
Basic weighted average shares used in computing net loss per common share55.7M shares1.4M shares
Diluted weighted average shares used in computing net loss per common share55.7M shares1.4M shares
Basic net loss per common share-$0.30-$10.19
Diluted net loss per common share-$0.30-$10.19

Compare PALISADE BIO, INC. with another company

Leadership

Who has led PALISADE BIO, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard Garr2007–2016
  2. Thomas Hallam2021–2022
  3. Mitchell Lawrence Jones2024

Chair

  1. Karl Johe2007–2008
  2. Kenneth C. Carter2019

President

  1. Richard Garr2007–2008

Chief financial officer

  1. Richard Garr2007
  2. John Conron2007–2011
  3. Jones Jonathan Brian Lloyd2015–2017
  4. Mitchell Lawrence Jones2024
2010201520202025
Board members and other officers (22)

Former names

  • Seneca Biopharma, Inc.Jan 28, 2020 to Apr 26, 20212
  • Neuralstem, Inc.Apr 3, 2006 to Jan 23, 20202

Timeline

  1. May 8, 2024New chief executive Mitchell Lawrence Jones becomes CEO11
  2. Apr 29, 2021New chief executive Thomas Hallam becomes CEO12
  3. Jan 29, 2007New chief executive Richard Garr becomes CEO13

Filings

403 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 121 insider forms, 42 large holders, 5 private raises, 154 other. The latest 20:

  1. Oct 7, 20264 EDGAR
  2. Oct 7, 20264 EDGAR
  3. Oct 5, 20264 EDGAR
  4. Aug 21, 20264 EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 13, 2026SCHEDULE 13G/A EDGAR
  7. Aug 10, 20268-K EDGAR
  8. Aug 10, 202610-Q EDGAR
  9. Jul 29, 2026SCHEDULE 13G EDGAR
  10. Jul 10, 20264 EDGAR
  11. Jul 8, 20264 EDGAR
  12. Jul 8, 20264 EDGAR
  13. Jul 8, 20264 EDGAR
  14. Jul 7, 2026144 EDGAR
  15. Jul 7, 2026144 EDGAR
  16. Jul 6, 20264 EDGAR
  17. Jun 18, 20264 EDGAR
  18. Jun 18, 20263 EDGAR
  19. Jun 12, 20264 EDGAR
  20. Jun 12, 20264 EDGAR

The 403 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 42 such filings since October 2021, the latest 10:

  1. Aug 14, 2026SCHEDULE 13G/A
  2. Aug 13, 2026SCHEDULE 13G/A
  3. Jul 29, 2026SCHEDULE 13G
  4. May 27, 2026SCHEDULE 13G
  5. May 15, 2026SCHEDULE 13G/A
  6. May 15, 2026SCHEDULE 13G/A
  7. May 15, 2026SCHEDULE 13G/A
  8. May 15, 2026SCHEDULE 13G
  9. May 15, 2026SCHEDULE 13G/A
  10. Feb 17, 2026SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 6, 2024Raised $4 million in a private offering of equity Form D: 1 investor so far Form D
  2. Feb 1, 2024Raised $2.5 million in a private offering of securities Form D: 15 investors so far Form D
  3. Apr 5, 2023Raised $4 million in a private offering of equity Form D: 9 investors so far Form D
  4. Jan 4, 2023Raised $2.5 million in a private offering of securities Form D: 6 investors so far Form D
  5. May 10, 2022Raised $2.4 million in a private offering of securities Form D: 5 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Soleus Capital Management, L.P.13,063,687$27.3M0.9%New
B Group, Inc.11,414,285$23.9M13.5%No change
Ameriprise Financial Inc11,081,434$23.2M0.0%−428,886
Jupiter Topco LLC10,689,452$22.4M0.0%New
BlackRock, Inc.10,436,760$21.8M0.0%+8,560,420
Octagon Capital Advisors LP10,276,317$21.5M2.0%No change
Perceptive Advisors LLC8,425,065$17.6M0.3%−503,084
Ra Capital Management, L.P.7,124,116$14.9M0.1%No change
Franklin Resources Inc5,785,189$12.1M0.0%No change
Point72 Asset Management, L.P.5,253,403$11.0M0.0%+4,841,631
Boxer Capital Management, LLC4,799,875$10.0M0.8%No change
Adage Capital Partners Gp, L.l.c.4,500,000$9.4M0.0%No change
Eversept Partners, LP4,182,785$8.7M0.5%−804,714
Geode Capital Management, LLC3,760,485$7.9M0.0%+2,214,245
Wellington Management Group Llp3,703,936$7.7M0.0%+799,025
Goldman Sachs Group Inc3,578,020$7.5M0.0%−1,795,931
Federated Hermes, Inc.3,136,607$6.6M0.0%No change
Squadron Capital Management LLC3,000,000$6.3M2.1%No change
Propel Bio Management, LLC2,582,388$5.4M2.8%+1,467,388
Vestal Point Capital, LP2,500,000$5.2M0.1%No change
State Street Corp2,475,648$5.2M0.0%+1,839,451
Morgan Stanley2,474,069$5.2M0.0%−2,077,464
Orbimed Advisors LLC2,333,000$4.9M0.1%No change
Great Point Partners LLC2,284,819$4.8M1.1%−1,120,938
Sphera Funds Management Ltd.2,257,106$4.7M0.7%+523,635

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36